Verona Pharma plc (NASDAQ:TARA) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totalling 4,000 shares, an increase of 400.0% from the February 27th total of 800 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily volume of 9,800 shares, the days-to-cover ratio is currently 0.4 days.
An institutional investor recently bought a new position in Verona Pharma stock. Victory Capital Management Inc. bought a new position in Verona Pharma plc (NASDAQ:TARA) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 992 shares of the company’s stock, valued at approximately $32,000. Victory Capital Management Inc. owned 0.18% of Verona Pharma as of its most recent SEC filing.
TARA opened at $22.01 on Friday. The company has a market cap of $140.23 million, a price-to-earnings ratio of -0.57 and a beta of 0.58. The stock’s fifty day moving average is $29.97. Verona Pharma has a fifty-two week low of $8.80 and a fifty-two week high of $152.40.
Verona Pharma Company Profile
ArTara Therapeutics, Inc develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.
Featured Article: Profit margin is different from the revenue
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.